NCT06969027

JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC

JS207 (PD-1/VEGF Dual Antibody) Combined With Chemotherapy in First-line Treatment of Advanced Non-small Cell Lung Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 84 (estimated)
• Sponsor: Shanghai Junshi Bioscience Co., Ltd. · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study targets patients with in first-line treatment of advanced NSCLC， enrolling 60-84 participants. Patients will receive Arm 1: JS207 (10 mg/kg or 15 mg/kg, IV, D1) + Pemetrexed (500 mg/m2 IV, D1) + a platinum (carboplatin AUC 5, D1 or cisplatin 75 mg/m2, D1), Q3W, for 4 cycles followed by JS207 (10 mg/kg or 15 mg/kg, IV, D1) + pemetrexed (500 mg/m2 IV, D1), Q3W, until meeting the treatment withdrawal criteria. Arm 2: JS207 (10 mg/kg or 15 mg/kg, IV, D1) + Paclitaxel (175 mg/m2 IV, D1) + a platinum (carboplatin AUC 5, D1 or cisplatin 75 mg/m2, D1), Q3W, for 4 cycles followed by JS207 (10 mg/kg or 15 mg/kg, IV, D1), Q3W, until meeting the treatment withdrawal criteria.The study aims to assess the safety, tolerability, and preliminary efficacy of JS207 combination therapy.

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	JS207	JS207 (10 mg/kg or 15 mg/kg, IV, d1)
DRUG	Pemetrexed injection	Pemetrexed (500 mg/m2 IV, D1)
DRUG	Platinum	Platinum (carboplatin AUC 5, D1 or cisplatin 75 mg/m2, D1)
DRUG	Paclitaxel	Paclitaxel (175 mg/m2 IV, D1)

Timeline

• Start date: 2025-06-19
• Primary completion: 2025-11-30
• Completion: 2027-12-31
• First posted: 2025-05-13
• Last updated: 2025-07-04

Locations

1 site across 1 country: China